Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05093231 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 13 to 17v5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 1, 2024 to Feb 26, 2025
    • Study sites: 0 to 13
    • Eligibility criteria shortened, about 45 words
    v4
  3. Primary completion date: Dec 31, 2025 to Jul 31, 2027
    • Start date: Jun 17, 2024 to Aug 1, 2024
    • Study completion date: May 4, 2026 to Jan 1, 2028
    v3
  4. Start date: Mar 3, 2022 to Jun 17, 2024
    • Eligibility criteria expanded, about 258 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with high tumour mutation burden
Trial Details
NCT Number NCT05093231
Lead Sponsor Cambridge University Hospitals NHS Foundation Trust
Collaborators: National Institute for Health Research, United Kingdom
Conditions
(from sponsor)		 Pancreatic Cancer
Related terms Pancreatic Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov